

Review on Atopic Dermatitis

Rajlaxmi Deolekar, Vaibhav J. Gajbe, Bilal Sufi, Vivek K. Gohane

New Montfort Institute of Pharmacy Asthi, Wardha, Maharashtra, India

vaibhavgajbe2468@gmail.com

Abstract: *Atopic dermatitis (AD) is becoming a major public health problem due to its increasing prevalence and growing evidence that it may cause other allergic reactions. Atopic dermatitis is a common inflammatory skin disease, with typical recurrent eczema lesions. This can be frustrating for children's patients, parents and healthcare providers. Pediatrics treats most children with atopic dermatitis because many patients do not have access to pediatric subspecialty physicians such as pediatric dermatologists and pediatric allergic doctors.*

Keywords: Atopic Dermatitis

REFERENCES

- [1]. Danby S, Cork MJ. A New understanding of atopic dermatitis: the role of epidermal barrier dysfunction and subclinical inflammation. *J Clin Dermatol.* 2010;1:33-46.
- [2]. Torres T. Atopic dermatitis: the new therapeutic revolution in dermatology. *Acta Med Port.* 2017;30:669–70
- [3]. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers.* 2018;4:1
- [4]. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human skin commensal bacteria protect against *Staphylococcus aureus* and are deficient in atopic dermatitis. *Sci Transl Med* 2017;9:eah4680.
- [5]. van Smeden J, Bouwstra JA. Stratum corneum lipids: their role for the skin barrier function in healthy subjects and atopic dermatitis patients. *Curr Probl Dermatol* 2016;49:8-26.
- [6]. de Bruin Weller MS, Rockmann H, Knulst AC, Bruijnzeel-Koomen CA. Evaluation of the adult patient with atopic dermatitis. *Clin Exp Allergy.* 2013 Mar;43(3):279-91. [PMID: 23414536].
- [7]. Finlay AY. Quality of life in atopic dermatitis. *J Am Acad Dermatol.* 2001 Jul;45(1 Suppl):S64-6. [PMID: 11423879].
- [8]. Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, Wahn U; Multicenter Allergy Study Group. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol.* 2004 May;113(5):925-31. [PMID: 15131576].
- [9]. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol Suppl (Stockh)* 1980;59:44-7.
- [10]. Bieber T. Atopic dermatitis. *N Engl J Med* 2008;358:1483-94.
- [11]. Choi WJ, Ko JY, Kim JW, Lee KH, Park CW, Kim KH, Kim MN, Lee AY, Cho SH, Park YL, Choi JH, Seo SJ, Lee YW, Roh JY, Park YM, Kim DJ, Ro YS. Prevalence and risk factors for atopic dermatitis: a cross-sectional study of 6,453 Korean preschool children. *Acta Derm Venereol* 2012;92:467-71
- [12]. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* 2006;38:441-6.
- [13]. Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis – a prospective follow-up to 7 years of age. *Allergy* 2000; 55: 240–245.
- [14]. Boguniewicz M, Leung DYM: New concepts in atopic dermatitis. *Compr Ther* 1996;22:144– 151.

- [15]. Morren M-A, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H: Atopic dermatitis: Triggering factors. *J Am Acad Dermatol* 1994;31:467–473.
- [16]. M. I. Asher, S. Montefort, B. Björkstén et al., “Worldwide ‘time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys,” *The Lancet*, vol. 368, no. 9537, pp. 733–743, 2006.
- [17]. H. C. Williams, “Atopic dermatitis,” *New England Journal of Medicine*, vol. 352, no. 22, pp. 2314–2366, 2005.
- [18]. J. M. Spergel, “From atopic dermatitis to asthma: the atopic march,” *Annals of Allergy, Asthma and Immunology*, vol. 105, no. 2, pp. 99–106, 2010.
- [19]. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*. 2018;4:1
- [20]. Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. *J Invest Dermatol*. 2014;134:1527–34.
- [21]. Sacki H, Oiso N, Honma M, Iizuka H, Kawada A, Tamaki K. Prevalence of atopic dermatitis in Japanese adults and community validation of the U.K. diagnostic criteria. *J Dermatol Sci*. 2009 Aug;55(2):140-1. [PMID: 19427173].
- [22]. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. *PLoS One*. 2012;7(7):e39803. [PMID: 22808063].
- [23]. Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. *J Invest Dermatol*. 2008;128(5):1067–1070
- [24]. Levin J, Friedlander SF, Del Rosso JQ. Atopic dermatitis and the stratum corneum: part 2: other structural and functional characteristics of the stratum corneum barrier in atopic skin. *J Clin Aesthet Dermatol*. 2013 Nov;6(11):49-54. [PMID: 24307926].
- [25]. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O’Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* 2006;38:441-6.
- [26]. K. Eyerich and N. Novak, “Immunology of atopic eczema: overcoming the Th1/Th2 paradigm,” *Allergy*, vol. 68, pp. 974– 982, 2013.
- [27]. C. N. A. Palmer, A. D. Irvine, A. Terron-Kwiatkowski et al., “Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis,” *Nature Genetics*, vol. 38, no. 4, pp. 441–446, 2006.
- [28]. A. de Benedetto, A. Kubo, and L. A. Beck, “Skin barrier disruption: a requirement for allergen sensitization,” *Journal of Investigative Dermatology*, vol. 132, no. 3, pp. 949–963, 2012.
- [29]. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol*. 1980;92:S44–7.
- [30]. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*. 2018;4:1.
- [31]. Waldman AR, Ahluwalia J, Udkoff J, Borok JF, Eichenfield LF. Atopic dermatitis. *Pediatr Rev*. 2018;39:180–93.
- [32]. Nutten S. Atopic dermatitis: global epidemiology and risk factors. *Ann Nutr Metab*. 2015;66:S8–16.
- [33]. Kapur S, Watson W, Carr S. Atopic dermatitis. *Allergy Asthma Clin Immunol*. 2018;14:S52.
- [34]. Silverberg JI. Adult-onset atopic dermatitis. *J Allergy Clin Immunol Pract*. 2019;7:28–33
- [35]. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*. 2018;4:1
- [36]. Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. *Br J Dermatol*. 2019;180:464–74.

- [37]. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med* 2002;347:1151-60.
- [38]. Hata TR, Gallo RL. Antimicrobial peptides, skin infections, and atopic dermatitis. *Semin Cutan Med Surg* 2008;27:144-50.
- [39]. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol.* 1980;92:S44-7.
- [40]. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol.* 2018y;32:657-82.
- [41]. Siegfried EC, Hebert AA. Diagnosis of atopic dermatitis: mimics, overlaps, and complications. *J Clin Forensic Med* 2015;4(5):884-917
- [42]. J. Ring, A. Alomar, T. Bieber et al., "Guidelines for treatment of atopic eczema (atopic dermatitis)—part I," *Journal of the European Academy of Dermatology and Venereology*, vol. 26, pp. 1045-1060, 2012
- [43]. E. L. Simpson, "Atopic dermatitis: a review of topical treatment options," *Current Medical Research and Opinion*, vol. 26, no. 3, pp. 633-640, 2010
- [44]. G. Ricci, A. Dondi, and A. Patrizi, "Useful tools for the management of atopic dermatitis," *American Journal of Clinical Dermatology*, vol. 10, no. 5, pp. 287-300, 2009.
- [45]. Illi S, von Mutius E, Lau S, et al; Multicenter Allergy Study Group. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol.* 2004;113(5):925-931
- [46]. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. *BMJ.* 2006; 332(7547):933-938
- [47]. . Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms asthma, allergic rhinocconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet.* 2006 Aug 26;368(9537):733-43. [PMID: 16935684].
- [48]. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. *J Am Acad Dermatol.* 1996 May;34(5 Pt 1):760-
- [49]. 4. [PMID: 8632070].
- [50]. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D Ständer S, Stingl G, Szalai S, Szepietowski JC, Taieb A, Werfel T, Wollenberg A, Darsow U; European Dermatology Forum; European Academy of Dermatology and Venereology; European Task Force on Atopic Dermatitis; European Federation of Allergy; European Society of Pediatric Dermatology; Global Allergy and Asthma European Network. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. *J Eur Acad Dermatol Venereol.* 2012 Sep;26(9):1176-93. [PMID:22813359].
- [51]. Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. *J Eur Acad Dermatol Venereol.* 2011 Jan;25(1):12-8. [PMID: 20569298].
- [52]. Fleischer AB Jr, Abramovits W, Breneman D, Jaracz E; US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. *J Dermatolog Treat.* 2007;18(3):151-7. [PMID: 17538803].
- [53]. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D Ständer S, Stingl G, Szalai S, Szepietowski JC, Taieb A, Werfel T, Wollenberg A, Darsow U; European Dermatology Forum; European Academy of Dermatology and Venereology; European Task Force on Atopic Dermatitis; European Federation of Allergy; European Society of Pediatric Dermatology; Global Allergy and Asthma European Network. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. *J Eur Acad Dermatol Venereol.* 2012 Sep;26(9):1176-93. [PMID:22813359].

- [54]. Dickel H, Bruckner TM, Schmidt A, Diepgen TL. Impact of atopic skin diathesis on occupational skin disease incidence in a working population. *J Invest Dermatol.* 2003 Jul;121(1):37-40. [PMID: 12839561].
- [55]. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D, Ständer S, Stingl G, Szalai S, Szepietowski JC, Taïeb A, Werfel T, Wollenberg A, Darsow U; European Dermatology Forum; European Academy of Dermatology and Venereology; European Task Force on Atopic Dermatitis; European Federation of Allergy; European Society of Pediatric Dermatology; Global Allergy and Asthma European Network. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. *J Eur Acad Dermatol Venereol.* 2012 Sep;26(9):1176-93. [PMID:22813359].
- [56]. Werfel T, Breuer K, Ruëff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, Kapp A. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, doseresponse study. *Allergy.* 2006 Feb;61(2):202-5. [PMID: 16409197].
- [57]. Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. *Acta Derm Venereol.* 2007;87(2):100-11. [PMID: 17340015].
- [58]. Draelos ZD. Therapeutic moisturizers. *Dermatol Clin.* 2000;18:597- 607
- [59]. Buraczewska I, Berne B, Linberg M, Torma H, Londen M. Change in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. *BJD.* 2007;156:492-8.
- [60]. Buraczewska I, Berne B, Linberg M, Torma H, Londen M. Change in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. *BJD.* 2007;156:492-8.
- [61]. Draelos ZD. Therapeutic moisturizers. *Dermatol Clin.* 2000;18:597- 607
- [62]. Anderson C, Dinulos JG. Are the new moisturizers more effective? *Curr Opin Pediatr.* 2009;21:486-90.
- [63]. Saijic D, Asiniwasis R, Skotnicki-Grant S. A look at epidermal barrier function in atopic dermatitis: Physiologic lipid replacement and the role of ceramide. *Skin Therapy Lett.* 2012;7:6-9.
- [64]. Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. *Dermatol Ther.* 2004;17:49-56
- [65]. Draelos ZD. Therapeutic moisturizers. *Dermatol Clin.* 2000;18:597- 607
- [66]. Anderson C, Dinulos JG. Are the new moisturizers more effective? *Curr Opin Pediatr.* 2009;21:486-90.
- [67]. Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. *Pediatr Dermatol* 1997; 14:321-4
- [68]. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol* 2014;71:327-49.
- [69]. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. *Br J Dermatol.* 2007;156(2):203–221
- [70]. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. *Br J Dermatol.* 2011;165(4):808–814
- [71]. Kojima R, Fujiwara T, Matsuda A, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. *Pediatr Dermatol.* 2013;30(1):29–35
- [72]. Huang JT, Abrams M, Tloutan B, et al. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics* 2009;123:e808-14
- [73]. Doege K, Grajecki D, Zyriax BC, Detinkina E, Zu Eulenburg C, Buhling KJ. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood: a meta-analysis. *Br J Nutr* 2012;107:1-6
- [74]. Pelucchi C, Chatenoud L, Turati F, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. *Epidemiology* 2012; 23:402- 14
- [75]. Klein P, Clark R. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. *Arch Dermatol* 1999;135(12):1522-5.
- [76]. Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. *Br J Dermatol.* 2019;180:464–74.

- [77]. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. *Cochrane Database Syst Rev.* 2012;15:CD005205
- [78]. Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta- analysis. *Epidemiology.* 2012;23:402–14
- [79]. Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future therapeutics. *Expert Rev Clin Immunol* 2012;8:189–197